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CHAPTER ONE.  GENERAL INTRODUCTION 
LITERATURE REVIEW 
Respiratory Syncytial Virus: An introduction   
Respiratory Syncytial Virus (RSV) is the leading cause of lower respiratory tract 
illness in infants worldwide, causing severe bronchiolitis and pneumonia.  In the United 
States alone, there are approximately 75,000 to 125,000 RSV-related hospitalizations and 
20,000 deaths per year, with an associated cost of $300 million (1-3).  Premature and 
newborn infants, as well as elderly and immunocompromised individuals, are the groups 
most susceptible to severe RSV infections.  Nearly 70% of children are infected within the 
first year of life and reinfection is common throughout adulthood (4, 5).  Neonatal RSV 
infection is of special significance not only because of the acute disease it causes but also 
because of the suggested link between early viral infection and the development of allergic 
asthma later in life (6).  
Bovine Respiratory Syncytial Virus (BRSV) is the etiological agent responsible for 
similar respiratory tract disease in cattle.  BRSV infection can cause severe disease alone as 
well as in concert with other viral or bacterial pathogens as part of the bovine respiratory 
disease complex (7).  BRSV infection causes severe pneumonia in young calves, and is 
responsible for considerable economic loss in the cattle industry worldwide.   Similar to 
infection rates in humans, 70% of calves born each year have been infected with BRSV by 
the age of 9 months to a year (8).   
While BRSV vaccines are commercially available, they are not 100% protective, and 
fail to provide long-term immunity.   Current challenges facing BRSV vaccination are the 
limited efficacy and duration of protection, the need to vaccinate immunologically immature 
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neonates, and the interference of maternal antibodies to RSV.  The two main goals in 
developing an efficacious RSV vaccine are: to activate cell-mediated immunity to clear the 
virus, and to provide long-lasting protection by inducing both T cell memory and antibody 
production to prevent reinfection (9). 
There is no safe and effective RSV vaccine currently available for use in humans.  In 
the 1960s, a formalin-inactivated RSV (FI-RSV) vaccine was tested in infants and children 
with unexpectedly disastrous results.  Vaccinated individuals developed severe RSV 
infections following natural exposure to the virus, of which two cases proved fatal (10).  It 
has been shown that priming with different RSV vaccines elicits a Th2 immune response 
upon secondary live RSV infection rather than a protective Th1 response. Studies using 
recombinant vaccinia viruses expressing the individual RSV G or F proteins primed a Th2 or 
Th1 response, respectively (11, 12).  In addition, the adjuvant used in RSV vaccine 
preparations can also affect the immune response (9).  The failed FI-RSV vaccine was alum-
adjuvanted, and led to vaccine-enhanced Th2 disease in test subjects.  Quillaja saponins have 
been used as a successful adjuvant in commercially available BRSV vaccines, and prime 
Th1-type protection (9).  Additional research with RSV subunit vaccines and synthetic CpG-
oligodeoxynucleotide adjuvants has also been shown to elicit a Th1 response in mice and 
rats, although one study reported enhanced lung pathology following challenge (13).  Further 
research based on these findings could contribute to the development of promising hRSV and 
BRSV vaccine candidates.  Challenges in human RSV vaccine research are the same as for 
BRSV, and include more stringent safety testing and regulations due to the history of and 
potential for vaccine-associated disease enhancement (9). 
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Virus structure and genomic organization 
RSV is an enveloped, non-segmented, negative sense RNA virus belonging to the 
Pneumovirus genus of the family Paramyxoviridae.  It acquires its lipid envelope upon 
budding from the host cell, which contains the virally-encoded glycosylated (G), fusion (F) 
and small hydrophobic (SH) proteins (Figure 1).  The matrix protein (M) forms a layer on the 
inner surface of the lipid envelope, surrounding  the viral genome and associated 
ribonucleoprotein complex, which is made up of the large (L) RNA-dependent-RNA-
polymerase, the nucleocapsid (N) protein and the phosphoprotein (P).   
The virion also contains two non-structural proteins (NS1 and NS1) which are 
believed to be regulatory in function, controlling viral RNA transcription and replication as 
well as host anti-viral IFNα/β signaling (14).  The RSV virion also contains two additional 
matrix proteins, the M2 factors M2-1 and M2-2, which are encoded by the same mRNA.  
M2-1 is a transcriptional elongator and anti-termination factor, and M2-2 is a regulatory 
protein that mediates the switch between viral gene transcription and replication(8).    
The viral genome is around 15,000 nucleotides long and helical in shape, encoding 
for 10 viral mRNAs which are translated into 11 viral proteins.  Starting at the 3’ end, the 
genes are transcribed in the following order, with those genes closer to the 3’ end having a 
higher frequency of transcription due to a polar transcription gradient:  NS1, NS2, N, P, M, 
SH, G, F, M2, and L.  Each viral gene is flanked by conserved sequences signaling the 
polyadenylation/termination of one transcript and a start signal for the transcription of the 
next downstream gene (15).  The full length viral genome also serves as the template for 
replication.  The switch from transcription to the initiation of replication of the genome is 
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mediated by the presence of the M2-1 protein, as well as 5’ regulatory sequences within the 
genome itself (16).          
Viral attachment and entry 
 Currently, the specific mechanism by which RSV virions attach and enter host cells is 
not completely understood.  Viral envelope proteins, F, G, and SH are thought to act in 
concert to bind to their specific host cell surface receptors, which remain unidentified.  
Studies have implicated Toll-like Receptor-4 and CD14 surface molecules in binding the F 
protein, and the fractalkine receptor (CX3CR-1) in binding the G protein (17, 18).  Receptor 
binding induces the reorganization of cellular membrane proteins and the recruitment of lipid 
rafts and additional receptors to the binding site.  Upon fusion, the viral lipid envelope 
becomes integrated into the host cell membrane, and virions enter the cytoplasm (15, 19).   
This viral uptake induces signaling pathways and ultimately activates NF-kB transcription 
factor.   
Animal models of RSV 
Animal models of RSV infection can be extremely valuable research tools for 
studying factors related to disease pathogenesis.  Animal models have many advantages and 
can be used to gain a better understanding of biological processes in order to predict how the 
human immune response will react to different stimuli including pathogens and vaccines.  
Manipulation and evaluation of animal models can help focus human clinical trials in terms 
of optimal dosages and routes of administration, and most importantly, decreasing the 
potential for adverse side effects (3). 
Formalin-inactivated BRSV (FI-BRSV) vaccines have been shown to have similar 
detrimental effects upon secondary virus exposure as the FI-RSV vaccine used in children in 
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the 1960s, suggesting that the BRSV model may offer important insight into human RSV 
vaccine research.  One study reported that while vaccination with FI-BRSV did induce viral 
G and F protein-specific IgG, no neutralizing antibodies were produced (20).  Further studies 
have shown similar results with partial protection, but also indicate disease enhancement in 
vaccinated individuals following secondary exposure to BRSV.  In one study, vaccinated 
calves had lower lung lesion scores, but exhibited an earlier onset of severe clinical signs 
with a resulting 30% mortality rate (21).  It is suggested that the disease enhancement is due 
to a priming of a Th-2 inflammatory response, resulting in eosinophilic infiltration and high 
levels of circulating BRSV-specific IgE (6, 22, 23).     
While cattle are the natural host for BRSV, other livestock species have been shown 
to become naturally infected with BRSV, including sheep, goats, llamas and bison (23-26).  
This fact, along with the structural and antigenic similarities between the human and bovine 
viruses, makes the use of animal models a valuable tool for studying RSV infection (27, 28).  
The lamb model of RSV infection is similar in terms of age-dependent susceptibility, with 
infected animals exhibiting similar clinical signs, disease progression, and pathological 
lesions as human infants infected with RSV (28-32).  
Host immune response to RSV  
 There is a great deal of variation in disease severity associated with RSV infection in 
children, which is likely a result of differences in regulation of the host response to the virus.  
It is unknown whether more severe RSV-associated pathology results from an overzealous 
immune response, a Th2-biased immune response, or an inadequate neonatal immune 
response (33).   
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Early innate immune responses to RSV infection shape the adaptive immune response 
through the production of immune mediators.  Early cytokine and chemokine expression 
induce trafficking of macrophages, eosinophils, neutrophils and NK cells to the lungs, 
leading to the activation of B and T cells.  Differential regulation of these events may be 
responsible for virus clearance as well as disease exacerbation (9). 
Neonatal immune response  
 There is evidence that a strong Th2 bias exists in the fetal immune system, as a 
mechanism for limiting dangerous inflammatory responses.  Increased levels of TNF-α and 
IL-1β have been shown to not only induce premature labor but may also be a factor for 
spontaneous abortion (34).  Increased IFN-γ at the fetal-maternal interface has been described 
to damage placental integrity and cause fetal loss as well (35).  In this regard, it appears that a 
Th2-biased immune response is beneficial through fetal development and at the time of birth, 
although it may contribute to the susceptibility of neonates to viral and bacterial infections 
during this time.   
 The neonatal immune system is faced with the challenges of protecting against 
infection while limiting inflammation, as well as transitioning to an antigen-rich environment 
after birth (36).  The respiratory tract is constantly exposed to antigen, and early infections 
likely play an important role in shaping the developing immune responses.  Studies in 
support of the hygiene hypothesis suggest that LPS-stimulation might inhibit the 
development of allergic disease by skewing the immune response away from the Th2 bias.       
 Because of their roles in innate immunity and antigen presentation, neonatal 
macrophage function is likely to be a major determinant of immune system maturation and 
development.  However, defects have been reported in neonatal macrophage function.  
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Macrophages isolated from neonatal mouse spleens were shown to have an increased IL-6 
and IL-10 secretion, but failed to secrete IL-1β, IL-12 or TNF-α, possibly due to reduced 
TLR-4 and CD14 surface expression, or the suppressive effects of IL-10 (37).  Another study 
using AMΦs from a rat model reported similar findings, where LPS-stimulated AMΦs 
exhibited decreased capacity to produce nitric oxide and IL-1β, as well as impaired 
phagocytic ability(38).   
Neonatal AMΦs isolated from premature infants with chronic lung disease had 
increased IL-1β and IL-6 secretion compared to healthy controls, indicating these cells had 
the capacity to produce these cytokines under the right conditions (39).  Macrophages 
derived from cord blood monocytes secreted IL-6 and TNF-α quickly in response to in vitro 
RSV infection (40).  In a lamb model, neonatal BRSV infection was shown to induce a 
mixed cytokine response in AMΦs, as evidenced by increased IL-4 and IL-10 gene 
transcripts in addition to significantly increased IL-1β and IL-8 gene expression (41).  The 
specific role of the AMΦ in initiation and modulation of the immune response to RSV in 
terms of active cytokine secretion remains unknown. 
Alveolar macrophages 
 Alveolar macrophages (AMΦs) are a primary innate immune cell in the lung, and are 
responsible for pathogen clearance, antigen presentation and cytokine production.  They are 
the most abundantly recovered cell type from bronchio-alveolar lavage (BAL) fluid, and are 
one of the first cell types to come into contact with inhaled microbes, toxins and antigens 
(42).  AMΦ functions in host defense include phagocytosis and intracellular killing of 
pathogens, secretion of oxygen metabolites, and cytokine production.  Initial pro-
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inflammatory cytokine production recruits additional immune cells including neutrophils to 
the site of infection.  This response is necessary for mounting an effective immune response, 
although it must be tightly regulated so as not to obstruct alveolar air exchange (43).  AMΦs 
appear to be somewhat self-regulating in that they also have anti-inflammatory activities.  
Following resolution of infections, AMΦs phagocytose apoptotic neutrophils to prevent the 
unintentional release of their contents.  This event reduces the release of pro-inflammatory 
cytokines and stimulates anti-inflammatory IL-10 and TGF-β production instead (44). 
RSV and alveolar macrophages 
It has been shown that AMΦs can support RSV replication by in vitro and in vivo 
studies (45, 46).  Early in vitro studies reported that human AMΦs are susceptible to RSV, 
but that infection is abortive.  Infected AMΦs exhibited increased TNF-α, IL-6 and IL-8 
cytokine secretion, of which only TNF-α appeared to be replication-dependent.  Treatment of 
bronchial epithelial cells with cell culture supernatants from RSV-infected AMΦs did not 
appear to confer any protection, indicating that the cytokine production from these cells has a 
role in modulating host inflammatory responses rather than direct anti-viral activities (47).  
Using a mouse model, another study reported that activated AMΦs had decreased viral loads 
compared with resting AMΦs, while increasing doses of virus resulted in an increased TNF-
α release, but a decrease in cytotoxic killing and production of reactive oxygen species (48). 
Large animal models of BRSV have shown bovine and ovine AMΦs to be permissive 
to infection with variable effects on AMΦ functions (49-53).  In vitro infection of bovine 
AMΦs with BRSV proved to be 80% abortive, indicating that some infected cells can, in 
fact, produce infective virus (49).  These infected AMΦs also exhibited decreased phagocytic 
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and killing functions, as well as an increase in neutrophil chemotactic factor release (49).  
Variable effects on macrophage function were observed in an ex vivo study, where BRSV 
inoculation was reported to inconsistently alter the AMΦ functions of phagocytosis, 
lysosomal killing and respiratory burst (53). 
BRSV located within ovine AMΦs has been positively identified by 
immunofluorescence (41, 52).  BRSV infection of ovine AMΦs induces the transcription of 
both proinflammatory (IL-1, IL-6, IL-8, IL-12p40, TNFα) and immunomodulatory (IL-4, IL-
10) cytokine genes (41).  Current gene expression data supports the suggestion of a mixed 
cytokine response of RSV-infected AMΦs, although whether or not this leads to translation 
and secretion of active cytokines is unknown. 
Th2 cytokines and RSV 
To date, only one study has shown a correlation between the development of 
wheezing and childhood asthma later in life to severe RSV bronchiolitis as infants (54).  This 
association could be a result of two possibilities:  either severe RSV is a causal agent for 
childhood asthma, or individuals who are already predisposed to asthma and allergy may be 
more susceptible to severe RSV infection.   
Although RSV has been implicated as a risk factor for the development Th2-type 
conditions, conflicting data from research to date prevents the RSV host immune response 
from fitting one definitive paradigm.  Increased IL-4/IFN-γ ratios have been observed in 
RSV-infected children compared to healthy controls, as well as in children with more severe 
RSV-induced bronchiolitis compared with those with more mild symptoms, suggesting an 
association between RSV and Th2 cytokine production (54, 55).  In contrast, other groups 
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have found no such association.  No correlation between clinical severity and Th2 cytokine 
production was found in infants under 6 months of age with mild or severe RSV infection, as 
shown by low plasma levels of IL-4 and IL-10 compared with increased plasma levels of IL-
6 and IL-8 (56).  In another study, there was no correlation found between wheezing in RSV-
infected infants and children and detection of Th2 cytokines in naso-pharyngeal secretions.  
A correlation was found, however, between MIP-1α production and disease severity (57).   
Moreover, the role of IL-10 expression in RSV infection is controversial.  Early 
studies reported that RSV infection effectively suppressed early immunoregulatory cytokines 
by inducing the expression of IL-10 (58).  However, other studies have shown that host IL-10 
production actually inhibits viral replication, and could have a potentially protective function 
(59).  RSV-bronchiolitis was found to be associated with an increased inflammatory 
response, with measured increases in IL-6, IL-8, IL-10, IFN-γ and MIP-1β, although those 
children with higher levels of inflammatory cytokines needed less extensive oxygen therapy 
(60).   
Taken together, these results indicate that RSV can induce both Th1 and Th2 cytokine 
expression, making it difficult to isolate those host factors which may contribute to more 
severe disease and which may actually have a protective role in children.  Further research is 
also needed to elucidate the various factors contributing to the vast differences in host 
responses.  
Immunomodulatory cytokines 
Interleukin-4 (IL-4)  
IL-4 is the main Th2-polarizing cytokine, and is responsible for the production of 
cytokines which trigger the differentiation of naïve T helper cells into Th2 cells, and  
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B cell Ig class switching to IgE (61, 62).  IL-4 is produced by immune cells including T cells, 
mast cells, basophils, eosinophils, as well as AMΦs (62, 63).  As cytokine production 
specifically by AMΦs affects the development of an adaptive immune response, IL-4 
production in these cells could effectively skew the Th1/Th2 cytokine balance in favor of a 
Th2 response.  The contribution of IL-4 protein secreted by AMΦs and its effect on the 
immune response to RSV is currently unknown. 
Splice variants of the IL-4 gene have been shown to exist in humans and cattle, and 
are suggested to have IL-4-antagonistic activity (64-66).  The splice variants IL-4δ2 and IL-
4δ3 result from the removal of exon 2 and exon 3, respectively, and are normally 
coexpressed with IL-4 (64, 66).  In humans, IL-4δ2 is preferentially expressed in cells from 
BAL fluid compared with PBMCs, and inhibits IL-4-induced T cell proliferation (64).  
Recent work in a bovine model of tuberculosis has suggested a role in protective immunity 
for IL-4δ3 expression (67).  As IL-4 antagonists, the IL-4 splice variants could have a 
protective role in modulating the effects of IL-4 production during RSV infection.  It will 
also be important for future studies reporting IL-4 production to specify the detection of full-
length versus splice variant mRNA or protein.  
Interleukin-10 (IL-10) 
 IL-10 is another anti-inflammatory cytokine induced during RSV infection.  It was 
initially described in as “cytokine synthesis inhibitory factor” because of its 
immunosuppressive functions (68).  It has been shown to inhibit Th1 cytokine production as 
well as antigen-presenting cell functions (69, 70).  In the lung, IL-10 is produced by alveolar 
macrophages in response to LPS stimulation and viral infections (71, 72).  RSV has been 
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shown to induce IL-10 secretion by healthy adult AMΦs(58).  IL-10 production by AMΦs 
during RSV infection could be a key factor in promoting the Th2 bias by inhibiting Th1 
cytokine production.  
Signaling pathways 
NFAT pathway 
NFAT (nuclear factor of activated T cells) is the transcription factor responsible for 
the expression of IL-4 and other cytokine genes in T cells and mast cells (73, 74).  The 
mechanism of IL-4 production by RSV-infected AMΦs is currently unknown.  Activation of 
the NFAT pathway in AMΦs by RSV could be a strategy employed by the virus to induce 
IL-4 gene expression and disrupt the Th1/Th2 balance in favor of a Th2 response. 
NFAT is activated upon calcium signaling in the cell, which activates calcium ion-
calmodulin binding, and the subsequent activation of calcineurin.  Calcineurin functions to 
dephosphorylate NFAT, which in turn exposes multiple nuclear localization signals, and 
allows NFAT to translocate to the nucleus (Figure 2).  In the nucleus, active NFAT binds 
DNA and its cofactor, AP-1 to induce cytokine gene transcription (75, 76).   
The immunosuppressive drugs, cyclosporin A (CsA) and tacrolimus (FK506), block 
calcineurin/NFAT interaction and prevent the activation and nuclear translocation of NFAT 
(77, 78).  Use of these drugs in research can be used to determine if IL-4 production in 
AMΦs occurs in a NFAT-dependent or NFAT-independent manner. 
NF-κB pathway 
 NF-κB is a well characterized inducible transcription factor made up of 3 subunits:  
p65 (Rel A) transactivator, p50 (RelB, c-Rel, NF-κB1), and p52 (NF-κB2)(79).  p50-p65 
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heterodimers make up the NF-κB complex, which contains a nuclear localization sequence 
(NLS).  IκB family members regulate NF-κB activity by binding and masking the NLS (80). 
 RSV attachment and entry activates intracellular signaling cascades that activate the 
IκB kinase family members IKKα and IKKβ, which phosphorylate IκB bound to NF-κB 
(81).  IκB phosphorylation induces its degradation and exposure of the NF-κB NLS.  This 
event allows NF-κB to translocate to the nucleus where it binds and activates cytokine gene 
transcription (79).   
 RSV has been shown to activate the NF-κB pathway in epithelial cells and alveolar 
macrophages both in vitro and in vivo, resulting in the production of IL-1,  
TNF-α, IL-6, IL-10, and IFN-β cytokines and the chemokines IL-8, MCP-1, MIP-1α (82, 
83).  Initial RSV binding to TLR4 or another host cell receptor may induce the signaling 
cascade necessary for NF-κB activation.  In an in vivo mouse model, NF-κB activation was 
shown to be TLR-4-dependent but viral replication-independent with the use of UV-
inactivated virus, as determined by electrophoretic mobility shift assay of nuclear extracts 
from whole lung tissue (84).  Other studies have used UV-inactivated RSV both in vitro and 
in vivo, and have shown that it induces IL-8, IL-6, TNF-a, and IL-10 cytokine gene 
expression, suggesting early recognition of the virus by innate pattern recognition receptors 
and induction of NF-κB gene transcription (33, 41).  Multiple signaling pathways including 
TLR-4 signaling, PI3-kinase signaling and the p38 MAPK pathways have been suggested to 
play a role in the immune response to RSV (19).  It is currently unknown which specific 
pathways or signaling molecules may be most critical in shaping the host immune response 
to RSV infection. 
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Mitogen-activated protein kinase (MAPK) signaling 
MAPK pathways are the signal transduction cascades responsible for the production 
of IL-10 and other cytokines in alveolar macrophages.  MAPK signaling is a highly 
conserved phosphorylation cascade activated in response to multiple extracellular stimuli 
such as environmental stresses and pro-inflammatory stimuli (85) (Figure 3).  MAP kinases 
were first identified as insulin-induced protein kinases, and were shown to be regulated by 
the dual phosphorylation of specific tyrosine and threonine residues by MAPK kinases (86).  
The MAPK kinases (MEK) themselves are activated by MEK kinases by another specific 
dual phosphorylation event (87, 88).  MAPK activation is tightly regulated by MAPK 
phosphatases (MKPs), also known as dual-specificiy phosphatases (DUSPs), which 
dephosphorylate the active-site threonine and/or tyrosine residues as part of negative 
feedback regulation (88).  To date, three different MAPK pathways have been identified:  
extracellular signal-regulated kinases (ERK), c-jun-N-terminal kinase (JNK) and p38 MAPK 
(89).   
 The p38 MAPK pathway is well-characterized, and has been shown to be necessary 
for cytokine gene transcription in LPS-stimulated AMΦs (72, 90).  It has also been shown to 
activate cytokine gene expression in response to viral infections, including RSV (91, 92).  
Activation of p38 MAPK modulates cytokine expression by phosphorylation of its two main 
targets, nuclear transcription factors and MAPK-activated protein kinase-2 (MAPKAP2).  
Activation of nuclear transcription factors directly induces cytokine gene expression, while 
MAPKAP2 activation affects mRNA stabilization.  Cytokine genes with AU-rich elements 
(ARE) in the 3’untranslated regions are targets for ARE-binding proteins activated by 
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MAPKAP2.  Activated ARE-binding proteins then bind and stabilize mRNA transcripts 
containing AREs, preventing their degradation (93).   
MAPK inhibitors 
  Small molecule inhibitors of MAPK signaling have been a valuable tool for studying 
these pathways, and are also being investigated as potential therapeutics for inflammatory 
diseases (94).  SB203580 is a pyridinyl imidazole compound that specifically binds the ATP-
binding site on p38 MAPK, causing a conformational change in the key interacting residues 
(89, 95).  This competitive inhibition effectively blocks the downstream actions of p38, and 
has been widely used in MAPK research to date.  Many studies using SB203580 have shown 
expression of IL-6, IL-8, IL-1β, TNF-α and IL-10 cytokines to be p38-MAPK dependent in 
rat and human models (72, 91, 96, 97).  SB203580 treatment has been shown, however, to 
have variable effects in different cell types.  In one study, p38 MAPK inhibition by 
SB203580 treatment decreased IL-6 and TNF-α gene expression in L929 fibrosarcoma cells 
and whole blood, but increased expression from 4-4 murine macrophages and peritoneal 
macrophages (98).  This observation suggests that p38 MAPK activation of cytokines may be 
cell-type specific, and could possibly have species-specific results as well.  
Treatment with SB203580 decreased IL-10 production in LPS-induced human 
AMΦs, as well as IL-1β and TNF-α production in RSV-infected epithelial cells (72, 92).  
The effect of p38 MAPK inhibition on IL-10 production in RSV-infected AMΦs has yet to 
be shown, and would provide insight into how the anti-inflammatory response of these cells 
is controlled.   
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OBJECTIVES AND SPECIFIC AIMS 
Statement of the Problem 
As described, RSV infection disrupts the Th1/Th2 cytokine balance, in favor of a 
predominantly Th2 immune response, which is a likely factor in the association between 
neonatal RSV infection and the development of allergies and asthma later in life.  The overall 
aim of the experiments described in the following chapter was to address the role of AMΦs 
in terms of cytokine expression and secretion during RSV infection.  These experiments 
examined cytokine responses in freshly isolated AMΦs from both neonatal and adult sheep 
infected in vitro with BRSV.   
Objective 1 
 Given that AMΦs upregulate the gene expression of IL-4 upon BRSV infection, 
determine if full-length IL-4 or splice variant mRNA transcripts are produced.  The 
production of IL-4 splice variant mRNA could potentially protect against IL-4 responses 
induced by RSV infection.  As described, IL-4 splice variants are normally coexpressed with 
full length IL-4 and result from removal of either exon 2 or exon 3 from full length IL-4 
mRNA.  Because the IL-4 splice variants are suggested to have IL-4-antagonistic activities, it 
is important to determine whether the changes in IL-4 mRNA levels are full length 
transcripts or the inactive splice variants. 
Hypothesis 1 
 IL-4/IL-4δ2 and IL-4/IL-4δ3 ratios will be increased in RSV-infected AMΦs 
compared to uninfected controls.   
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Specific aim 1 
 IL-4 and IL-4 splice variant mRNA was measured by real-time PCR.  Taqman assay 
with oligonucleotide primers and fluorescent probes were used for increased sensitivity in 
detecting full length IL-4 versus splice variant mRNA. 
Objective 2 
 Determine if the increases seen in IL-4 mRNA in RSV-infected AMΦs results in an 
increased level of secreted IL-4 protein, which could contribute to the overall Th2 
environment seen during RSV infection in both neonates and adults.  Increased IL-4 
secretion from neonatal AMΦs could help in explaining more severe disease seen in infants 
compared with adults. 
Hypothesis 2 
 RSV-infected AMΦs will secrete increased amounts of IL-4 protein due to the 
increase in IL-4 gene expression.  Secreted IL-4 protein from neonatal AMΦs will be higher 
than adults. 
Specific aim 2 
 Optimized IL-4 ELISA for detection of ovine IL-4 protein, and measured IL-4 protein 
levels secreted in cell culture supernatants from neonatal and adult AMΦs infected with 
RSV. 
Objective 3 
 Determine if IL-10 is secreted by AMΦs in response to RSV infection, which could 
be a contributing factor to the modulation of the immune response.  
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Hypothesis 3 
AMΦs produce the anti-inflammatory cytokine IL-10 in response to RSV infection, 
and IL-10 levels produced in neonatal AMΦs will be higher than that from adult cells. 
Specific Aim 3 
 Measured IL-10 protein levels in cell culture supernatants from neonatal and adult 
AMΦs infected with RSV or stimulated with mitogen. 
Objective 4 
 Determine the proinflammatory IL6, IL-8 and IL-1β cytokine production by RSV-
infected AMΦs from neonates and adults. 
Because RSV pathogenesis is associated with a mixed immune response and the 
production of both immunomodulatory and proinflammatory mediators, AMΦ production of 
proinflammatory cytokines may contribute to the differences observed in the severity of 
disease observed in neonates compared to adults.   
Hypothesis 4 
 In addition to immunomodulatory cytokine gene transcription, AMΦs upregulate the 
proinflammatory cytokines IL-6, IL-8 and IL-1β in response to RSV infection.  Increases in 
IL-1β gene transcription will lead to increases in IL-1β protein secretion by AMΦs due to 
RSV infection, with higher levels from neonatal AMΦs. 
Specific aim 4 
 Quantified IL-6, IL-8 and IL-1β mRNA expression by real time PCR using SYBR 
green chemistry.  Measured IL-1β protein secretion by ELISA. 
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Objective 5 
 Elucidate the role of MAPK signaling pathways involved in cytokine expression by 
RSV-infected AMΦs through the use of SB203580, the specific chemical inhibitor for p38 
MAPK. 
Hypothesis 5 
 Selective inhibition of p38 MAPK signaling will decrease IL-10 and pro-
inflammatory cytokine production by RSV-infected AMΦs. 
Specific aim 5 
 In vitro RSV infection was initiated after pre-incubation with the p38 MAPK 
inhibitor, SB203580.  Cytokine expression was quantified by real time PCR using SYBR 
green chemistry.  Secreted IL-4, IL-10 and IL-1β protein was detected by ELISA. 
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Figure 1.  RSV virion structure.  RSV is an enveloped, non-segmented, negative sense RNA 
virus.  It acquires its lipid envelope upon budding from the host cell, which contains the 
virally-encoded glycosylated (G), fusion (F) and small hydrophobic (SH) proteins.  The 
matrix protein (M) forms a layer on the inner surface of the lipid envelope, surrounding the 
viral genome and its associated ribonucleoprotein complex, made up of the large (L) RNA-
dependent-RNA-polymerase, the nucleocapsid (N) protein and the phosphoprotein (P).  M2 
factors M2-1 and M2-2 are associated with the M protein layer.   
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Figure 1.  Adapted from Valarcher and Taylor. Veterinary Research 38 (2007) 153-180. 
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Figure 2.  Proposed pathway leading to IL-4 production in macrophages.  NFAT is activated 
upon calcium signaling in the cell, which activates calcium ion-calmodulin binding, and the 
subsequent activation of calcineurin.  Calcineurin functions to dephosphorylate NFAT, which 
in turn exposes multiple nuclear localization signals, and allows NFAT to translocate to the 
nucleus.  In the nucleus, active NFAT binds DNA and its cofactor, AP-1 to induce cytokine 
gene transcription.  Cyclosporin A (CsA) and tacrolimus (FK506), block calcineurin/NFAT 
interaction and prevent the activation and nuclear translocation of NFAT.   
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Figure 2.  Adapted from Serfling et al. The International Journal of Biochemistry & Cell 
Biology 36 (2004) 1166-1170. 
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Figure 3.  Overview of p38 MAPK signaling in alveolar macrophages.  MAPK signaling is 
activated in response to multiple extracellular stimuli such as environmental stresses and pro-
inflammatory stimuli.  Upon activation, MEK kinases (MEKK) phosphorylate MAPK 
kinases (MEK) by a specific dual phosphorylation event.  Active MEK phosphorylates MAP 
kinases including p38, ERK and JNK by another dual phosphorylation event.  Multiple 
targets of p38 include MAPK-activated protein kinase-2 (MAPKAP2) and nuclear 
transcription factors.   
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Figure 3.  Adapted from Haddad et al. Cellular Signalling 15 (2003) 255-267. 
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CHAPTER TWO.  NEONATAL ALVEOLAR MACROPHAGES UPREGULATE 
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Abstract  
 Respiratory syncytial virus (RSV) is a leading cause of bronchiolitis and pneumonia 
in premature and newborn infants.  We examined the role of alveolar macrophages (AMΦs) 
in a model of RSV infection.  Additionally, the contribution of MAPK signaling to cytokine 
expression was delineated via p38 inhibitor SB203580.  AMΦs isolated from neonatal and 
adult sheep were infected with BRSV in vitro with or without SB203580 pre-treatment.  
Expression of cytokine mRNA and protein secretion was determined.  Results showed that 
RSV infection induced IL-1β, IL-4, IL-6, IL-8, and IL-10 gene expression.  Furthermore, 
RSV induction of IL-6, IL-8 and IL-1β mRNA in neonatal and adult AMΦs, as well as IL-10 
protein from adult AMΦs, was p38 MAPK-dependent.  Significantly higher IL-1β mRNA 
was detected in RSV-infected neonatal AMΦs than adult cells.  Paradoxically, neonatal 
AMΦs did not secrete IL-1β, IL-4, or IL-10.  Inhibition of cytokine secretion by RSV may 
contribute to the increased susceptibility and severity of disease in neonates. 
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1.  Introduction 
Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract 
illness in infants worldwide, causing severe bronchiolitis and pneumonia.  Premature and 
newborn infants are most susceptible to RSV infection, in addition to elderly and 
immunocompromised individuals.  Neonatal RSV infection is of particular interest due to the 
suggested link between early RSV infection and the development of allergic asthma later in 
life (1-3).    
Bovine Respiratory Syncytial Virus (BRSV) is the etiological agent responsible for 
similar respiratory tract disease in cattle.  BRSV causes severe pneumonia in young calves, 
and is responsible for considerable economic loss in the cattle industry worldwide.   
Additionally, BRSV induces a Th2-biased immune response in calves, as indicated by the 
production of virus-specific IgE and IL-4 in lymph cells from infected calves (4). 
Modulation of the immune response to RSV and Th2 cytokine production are 
possible factors in the association between neonatal RSV infection and the development of 
allergic asthma.  AMΦs are critical for early innate immune responses in the lung through 
phagocytic activity and antigen presentation to immune effectors.  Production of cytokines 
by AMΦs affects the development of an adaptive immune response, and could effectively 
skew the Th1/Th2 cytokine balance.   
Previous gene expression studies have shown RSV-infected AMΦs upregulate 
immunomodulatory IL-4 and IL-10 mRNA transcripts, which could contribute to an overall 
Th2-type environment in the lung (5).  Splice variants of the IL-4 gene have been shown to 
exist in humans and cattle, and are suggested to have IL-4-antagonistic activity (6-9).  The 
splice variants IL-4δ2 and IL-4δ3 result from the removal of exon 2 and exon 3, respectively, 
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and are normally coexpressed with full-length IL-4.  As IL-4 antagonists, the IL-4 splice 
variants could have a protective role in modulating the effects of IL-4 production during RSV 
infection.  Therefore, it is imperative to differentiate between full-length IL-4 and the 
biologically-inactive splice variants.  Here, we report that IL-4 mRNA transcripts induced by 
BRSV in AMΦs contain the full-length sequence and are not splice variant mRNA.   
Cytokine production by AMΦs is critical for the switch from innate to adaptive 
immunity.  To further characterize the effects of cytokine production by AMΦs on the 
immune response to BRSV infection, we investigated IL-4 and IL-10 secretion in addition to 
gene expression.  Adult human AMΦs secrete IL-4 protein upon stimulation with PMA and 
ionomycin and IL-10 protein following LPS stimulation, but this has yet to be shown in 
neonatal AMΦs (10, 11).  IL-4 protein secretion was not detected from neonatal or adult 
AMΦs treated with either BRSV or the combination of PMA and ionomycin in vitro.  
Neonatal AMΦs secreted negligible amounts of IL-10 protein in response to either BRSV or 
mitogen stimulation, while adult AMΦs secreted increased levels of IL-10 protein following 
BRSV or mitogen stimulation. 
 The data presented herein suggest that neonatal AMΦs are not a source of anti-
inflammatory cytokines during RSV infection.  Rather, pro-inflammatory cytokine 
production by AMΦs could contribute to the lung pathology and inappropriate immune 
response observed during neonatal RSV infection.  The induction of IL-6, IL-1β and IL-8 
gene transcripts by RSV has been previously reported in peripheral blood monocytes from 
human infants, as well as AMΦs from mice and sheep (5, 12, 13).  Here, we investigated 
whether the increases in cytokine message are translated into increases in secreted protein 
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from AMΦs.  Increased expression of pro-inflammatory cytokine genes IL-1β and IL-8 were 
detected in BRSV-infected AMΦs obtained from both neonatal and adult sheep.  
Significantly more IL-1β mRNA transcripts were detected in BRSV-infected AMΦs from 
neonates compared with those from adult sheep.  However, negligible IL-1β protein was 
detected from BRSV-infected AMΦs.   
 To date, the effect of BRSV infection on signaling pathways and mechanisms of 
cytokine production has not been well-studied in neonatal AMΦs.  Here, we examined the 
role of p38 MAPK signaling in BRSV-infected AMΦs from both neonates and adult sheep 
through the use of a specific chemical inhibitor of p38 MAPK, SB203580.  IL-6, IL-8 and 
IL-1β gene expression levels were lower in neonatal and adult AMΦs pre-treated with 
SB203580 prior to BRSV- or LPS-stimulation compared to BRSV- or LPS-stimulation alone.   
2.  Materials and Methods 
2.1.   Sample collection 
 Lungs were harvested from healthy adult sheep (n=8) or neonatal lambs (n=8) and 
lavaged with sterile PBS.  Bronchioalveolar lavage fluid was centrifuged at 805 x g for 15 
minutes, resuspended in sheep-specific alveolar macrophage culture medium (RPMI-1640 
(Invitrogen, Carlsbad, CA) supplemented with 2% sheep serum, 25mM HEPES, 2mM L-
glutamine, 1% antibiotic/antimycotic and 0.02mg/mL Gentamicin) and plated in 150x15mm 
plastic petri dishes.  Cells were incubated for 2h at 37°C/5%CO2 to allow for macrophage 
adherence.  Adherent cells were washed 2 times with sterile PBS and gently scraped into 
15mL sheep alveolar macrophage medium.  Harvested cells were pelleted by centrifugation 
at 453 x g for 10 minutes at 4°C and then resuspended in sheep alveolar macrophage medium 
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for counting by hemacytometer.  5x105 cells were plated in 200μl medium per well in 96-
well round-bottom tissue culture plates and incubated at 37°C/5%CO2. 
2.2.   p38 MAPK inhibition 
 Designated AMΦs were pre-incubated with p38 MAPK inhibitor SB203580 (Biomol, 
Plymouth Meeting, PA) diluted in sheep alveolar macrophage medium at 25μM in-well 
concentration for 1 hour at 37°C/5%CO2.  This working concentration was determined in 
preliminary experiments.  
2.3.   In vitro BRSV infection and mitogen stimulation 
 BRSV-375 was added at a multiplicity of infection (moi) of 1 pfu/cell and incubated 
at 37°C/5%CO2 for 90 minutes.  Cells were washed 2 times and fresh culture medium added.  
LPS-stimulated cells were treated with LPS from E. coli 055:B5 (Sigma, St. Louis, MO) at 
1μg/mL in-well concentration.  Phorbol-12-myristate-13-acetate (PMA) and ionomycin 
(Sigma) were added at 1μg/mL and 0.5μg/mL, respectively in PMA/ionomycin-stimulated 
AMΦs.  Cells were collected in RLT lysis buffer from RNeasy Mini kit (Qiagen, Valencia, 
CA) at 2, 6, 12, 24h for RNA isolation and stored at -80°C until use.  Supernatants were 
collected and frozen at 24h, 48h and 72h for protein detection by ELISA. 
2.4.   RNA extraction and First-Strand cDNA synthesis 
 Total RNA was isolated using RNeasy Mini Kit (Qiagen, Valencia, CA) according to 
manufacturer’s instructions, including an on-column RNase-free DNase digestion step to 
remove any contaminating genomic DNA.  RNA yield and purity were determined on 
GeneQuant-pro spectrophotometer (GE Healthcare, Piscataway, NJ).  400 ng total RNA was 
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reverse transcribed using Superscript II Reverse Transcriptase (Invitrogen, Carlsbad, CA) 
and oligo(dT)12-18 primers (Invitrogen). 
2.5.   Real-time PCR Taqman assay for IL-4 (full length), IL-4δ2 and IL-4δ3 mRNAs 
 Quantitative real-time reverse transcriptase PCR (qRT-PCR) was performed using the 
SuperScriptIII Platinum One-Step qRT-PCR kit with ROX (Invitrogen) in a 30 μl reaction 
volume with 250-500 ng total RNA.  No-RT control (NRC) samples were performed with 
Platinum qPCR Supermix-UDG with ROX (Invitrogen).   
 Oligonucleotide primer and probe sets used are listed in Table 1 and were modified 
from published bovine sequences (Waldvogel 2004).  qRT-PCR reactions were run on an 
Applied Biosystems 7300 Real-time PCR System with the following conditions: 49°C for 30 
min, 95°C for 2 min, followed by 50 cycles of 95°C for 15s, 50°C for 30s and 72°C for 30s.    
2.6.   Real-time PCR SYBR green assay for IL-4, IL-10, IL-6, IL-8, IL-1β mRNAs 
 Oligo(dT) cDNA was diluted 1:10, and 2μl used per reaction.  Real-time PCR 
reactions were performed using SYBR Green PCR Mastermix (Applied Biosystems, Foster 
City, CA) in a 20μl reaction volume.  Primers used are listed in Table 2 and reaction 
conditions were as follows:  10 min at 95°C, followed by 40 cycles of 95°C for 15s and 50°C 
for 1 min, and a dissociation step of 95°C for 15s, 50°C for 20s, 95°C for 15s and 60°C for 
15s. 
Expression of ovine polyubiquitin gene was used as the endogenous control for 
calculation of dCt values.  Relative quantification of RT-PCR data was determined by the 
2−(ddCt) method (Livak and Schmittgen, 2001).   
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2.7.   IL-4 Enzyme-linked immunosorbent assay (ELISA) 
 Secreted IL-4 protein was detected in cell culture supernatants by sandwich ELISA.  
Briefly, Immunolon 2HB microtiter plates (Thermo Scientific, Franklin, MA) were coated 
with 100μl per well of mouse anti-bovine IL-4 antibody clone CC313 (Serotec, Raleigh, NC) 
diluted 5μg/mL in 0.5M carbonate-bicarbonate buffer (pH 9.6), and incubated at 4°C 
overnight.  Plates were washed 5 times between each step with 300μl per well of washing 
buffer (PBS + 0.05% Tween20), and blocked with 100μl blocking buffer (PBS + 1% BSA + 
0.05% Tween20) per well for 1h at 37°C.  Serial dilutions of recombinant bovine IL-4 
protein standard and sample supernatants were added in duplicate wells and incubated for 1h 
at 37°C.  Biotinylated mouse-anti-bovine IL-4 antibody clone CC314 (Serotec, Raleigh, NC) 
was diluted to 2.5μg/mL in blocking buffer and 100μl added per well for detection.  
Streptavidin-HRP conjugate (GE Healthcare, Piscataway, NJ) was diluted 1:1000 in blocking 
buffer and 100μl added per well.  Wells were developed with 100μl per well of ABTS 
substrate (US Biological, Swampscott, MA).  Color development was measured after 10 min 
by measuring absorbance at 405 nm with a FlexStation3 microplate reader (Molecular 
Devices, Sunnyvale, CA).  Recombinant bovine IL-4 protein (Serotec, Raleigh, NC) was to 
generate a standard curve, and used to calculate concentration of IL-4 in sample supernatants.  
The limit of detection of this assay was found to be 32pg/mL.   
2.8.   IL-10 ELISA 
Secreted IL-10 was detected in cell culture supernatants by sandwich ELISA.  
Briefly, MaxiSorp microtiter plates (Nunc, Rochester, N.Y.) were coated with 100μl per well 
mouse anti-bovine IL-10 antibody (Serotec, Raleigh, NC) diluted 4μg/mL in 0.5M 
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carbonate-bicarbonate buffer (pH 9.6) and incubated overnight at 37°C.  Plates were washed 
5 times between each step with 300μl per well of washing buffer (PBS + 1% Tween 80) per 
well and then blocked with 100μl blocking buffer (PBS + 1% gelatin) per well for 1h at 
37°C.  Serial dilutions of recombinant bovine IL-10 protein standard and sample supernatants 
were added in duplicate wells and incubated for 1h at 37°C.  Biotinylated mouse anti-bovine 
IL-10 (Serotec, Raleigh, NC) detection antibody was added per well at 1μg/mL in blocking 
buffer.  Streptavidin-HRP conjugate (GE Healthcare, Piscataway, NJ) was diluted 1:800 in 
blocking buffer and 100μl added per well.  Wells were developed with 100μl per well of 
ABTS substrate (US Biological, Swampscott, MA).  Color development was measured after 
30 min by measuring absorbance at 405 nm with a FlexStation3 microplate reader 
(Molecular Devices, Sunnyvale, CA).  Standard curves were generated from recombinant 
bovine IL-10 protein (J.C. Hope, Institute of Animal Health, Compton, UK) and were used to 
calculate concentration of IL-10 ELISA units/mL in sample supernatants.   
2.9.   IL-1β ELISA 
Secreted IL-1β was detected in cell culture supernatants by ELISA.  Briefly, 
MaxiSorp microtiter plates (Nunc, Rochester, N.Y.) were coated with 100μl per well rabbit 
anti-bovine IL-1β antibody (Thermo Scientific, Rockford, IL) diluted 5μg/mL in 0.5M 
carbonate-bicarbonate buffer (pH 9.6) and incubated overnight at 37°C.  Plates were washed 
5 times between each step with 300μl per well of washing buffer (PBS + 0.05% Tween 20) 
per well and then blocked with 100μl blocking buffer (Milk blocking buffer (Kirkegaard & 
Perry Laboratories, Gaithersburg, MD)) per well for 1h at 37°C.  Serial dilutions of 
recombinant bovine IL-1β protein standard and sample supernatants were added in duplicate 
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wells and incubated for 1h at 37°C.  Biotinylated rabbit anti-bovine IL-1β (Thermo 
Scientific, Rockford, IL) detection antibody was added per well at 10μg/mL in blocking 
buffer.  Streptavidin-HRP conjugate (GE Healthcare, Piscataway, NJ) was diluted 1:250 in 
blocking buffer and 100μl added per well.  Wells were developed with 100μl per well of 
TMB microwell substrate (Kirkegaard & Perry Laboratories, Gaithersburg, MD).  Color 
development was measured after 20 min by measuring absorbance at 650 nm with a 
FlexStation3 microplate reader (Molecular Devices, Sunnyvale, CA).  Standard curves were 
generated from recombinant bovine IL-1β protein (Serotec, Raleigh, NC) and were used to 
calculate concentration of IL-1β in sample supernatants.   
3.  Results 
3.1.  Alveolar macrophages produce full-length IL-4 mRNA transcripts in response to BRSV 
infection. 
 AMΦs harvested from neonatal and adult sheep lungs were stimulated in vitro with 
BRSV or PMA and ionomycin to assess IL-4 gene expression and protein secretion.  Specific 
primers and probe sets were used to detect full-length IL-4 or splice variant mRNA 
transcripts by RT-PCR.  BRSV induced a 7-fold increase in full-length IL-4 expression and a 
2-fold increase in adult and neonatal AMΦs, respectively, at 24h post-infection compared to 
mock-treated controls.  PMA and ionomycin-treated AMΦs had significant increases in full-
length IL-4 transcription as well, with an average of 10 and 20-fold increase in full-length IL-
4 expression at 6h post-infection in neonates and adults (Figure 1).  No splice variant mRNA 
was detected in any of the samples in any of the  treatment groups.   
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 To assess whether the observed increases in IL-4 mRNA transcripts leads to increases 
in IL-4 protein levels, cell-culture supernatants from the in vitro BRSV- or PMA and 
ionomycin-treated AMΦs were harvested at 24 and 48h, and tested for secreted IL-4 protein 
by ELISA.  Dilutions of recombinant bovine IL-4 protein were used to create a standard 
curve, and the limit of detection of the assay was found to be 32pg/ml.  Cell-culture 
supernatants from magnetically-sorted ovine CD4+ T cells isolated from peripheral blood, 
stimulated with PMA and ionomycin for 24h were included as a positive control.  IL-4 
protein was not detected in supernatants from BRSV-infected or PMA and ionomycin-
stimulated AMΦs (data not shown). 
3.2.  IL-10 production by adult alveolar macrophages is induced by in vitro BRSV infection 
or LPS stimulation and is dependent on p38 MAPK signaling.   
 AMΦs harvested from neonatal and adult sheep were treated in vitro with SB203580, 
to block p38 MAPK signaling upon BRSV-infection or LPS-stimulation.  IL-10 mRNA 
transcripts detected by real-time PCR were expressed relative to control AMΦs.  No 
significant differences in IL-10 expression were observed in either neonatal or adult AMΦs 
treated with BRSV or LPS compared to mock-treated cells.  Adult AMΦs pre-incubated with 
SB203580 prior to LPS stimulation exhibited a trend of lower IL-10 mRNA transcripts 
compared to LPS treatment alone (Figure 2).   
 Secreted IL-10 protein was measured by sandwich ELISA.  Treatment with either 
BRSV, LPS, or PMA and ionomycin increased IL-10 secretion from adult AMΦs.  Pre-
incubation with SB203580 effectively decreased IL-10 secretion in mock-treated, BRSV-
infected and LPS-treated AMΦs from adult sheep to levels lower than controls, on average 
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(Figure 3B).  Minimal IL-10 protein was detected in cell culture supernatants from neonatal 
AMΦs infected with BRSV or treated with PMA/ionomycin (Figure 3A).  The outliers 
observed in neonatal AMΦ IL-10 secretion represent samples from the same animal.  The 
high level of IL-10 detected in the mock-infected sample suggests a pre-existing condition, 
and therefore changes in IL-10 secretion in samples from this animal can not be specifically 
attributed to the in vitro BRSV infection or SB203580 treatment. 
3.3.  BRSV infection induces increased pro-inflammatory cytokine gene expression in AMΦs 
from neonates compared to adults 
 Transcription of proinflammatory cytokine genes IL-6, IL-8 and IL-1β were 
measured in response to in vitro BRSV infection in neonatal and adult AMΦs in the presence 
or absence of SB203580 pre-treatment.  No significant differences were observed in IL-6 
mRNA transcripts between mock- and BRSV-infected AMΦs in neonates or adults.  
However, LPS stimulation of adult AMΦs induced a two-fold increase in expression at 24h.  
Pre-treatment with SB203580 prior to LPS stimulation induced less IL-6 transcription in 
adult AMΦs compared to cells treated with LPS only (Figure 4A). 
 IL-8 gene expression was increased in both neonatal and adult AMΦs infected with 
BRSV compared to mock-infected cells, with a two-fold increase at 12h in both age groups 
(Figure 4B).  BRSV-treated AMΦs that were pre-incubated with SB203580 exhibited IL-8 
gene expression either equal to or less than that of control cells.  LPS stimulation of adult 
AMΦs induced a significant (p<0.05) 5.5-fold increase in IL-8 transcription compared to 
mock-treated control cells.  Pre-treatment with SB203580 prior to LPS stimulation induced 
only a 4.5-fold increase in IL-8 expression compared to controls (Figure 4B). 
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 BRSV-treatment of neonatal AMΦs induced a significant (p<0.01) increase in IL-1β 
transcripts compared with mock-treated cells, which was reduced by pre-incubation with the 
p38 MAPK inhibitor SB203580.  Neonatal AMΦs pre-incubated with SB203580 had IL-1β 
transcription levels less than or equal to levels in mock-treated cells.  No significant 
differences in IL-1β gene expression were observed in adult AMΦs treated with BRSV or 
LPS (Figure 4C). 
3.4.  Neonatal AMΦs are not a significant source of IL-1β protein during RSV infection 
 Freshly isolated AMΦs from adult (n=8) or neonatal (n=8) sheep were stimulated in 
vitro with BRSV, following pre-incubation with p38 MAPK inhibitor, SB203580, or culture 
medium alone.  LPS- and PMA and ionomycin- stimulated AMΦs were included as positive 
controls.  Cell culture supernatants were harvested at 24h or 48h, and frozen at -80C until 
use.  Supernatants were screened for IL-1β protein by sandwich ELISA.  Low levels of 
secreted IL-1β were detected at 24h in neonatal AMΦs infected with BRSV with or without 
SB203580 pretreatment (Figure 5A).  An increase in IL-1β protein secretion by neonatal 
AMΦs was observed only in the subset treated with PMA and ionomycin (Figure 5A).  Adult 
AMΦs secreted increased levels of IL-1β in response to LPS-stimulation, which was 
quantitatively larger than that in mitogen-stimulated neonatal AMΦs.  No increase in IL-1β 
secretion was observed in adult AMΦs following BRSV infection at 24h (Figure 5B).  
Similar results were observed at 48h, with less IL-1β detected in supernatants from both 
neonatal and adult AMΦs (Figure 6A and 6B). No significant effects of p38 MAPK 
inhibition on IL-1β protein secretion were observed in either age group at 24 or 48h.  
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4. Discussion 
 The aim of the present study was to further elucidate the role of the AMΦ during the 
host response to RSV infection in neonates and adults.  In this study, we compared cytokine 
production in AMΦs from neonatal (age ≤ 7d) and adult (age 1-3y) sheep.  Here, we report 
that RSV infection induces the expression of both anti-inflammatory (IL-4, IL-10) and pro-
inflammatory (IL-8, IL-1β) cytokine genes in AMΦs.  Moreover, p38 MAPK signaling was 
shown to be necessary for IL-6, IL-8 and IL-1β gene transcription in neonatal and adult 
AMΦs, as well as IL-10 protein secretion from adult AMΦs.  Significantly higher IL-1β 
mRNA was detected in RSV-infected AMΦs from neonates compared to adults.  However, 
IL-1β, IL-4, or IL-10 protein was not detected in cell culture supernatants from RSV-infected 
neonatal AMΦs.     
It has been previously shown that AMΦs elicit a mixed cytokine response following 
RSV infection, as indicated by increases in both pro- and anti-inflammatory cytokine gene 
expression (5, 14).  To further investigate this response, the first aim of these studies was to 
explore how the changes in cytokine gene expression are reflected in corresponding changes 
in cytokine protein secretion.   
 Because of the suggested link between neonatal RSV infection and the development 
of Th2-associated conditions later in life (1, 2), we first examined IL-4 production.  Recent 
work has reported the detection of IL-4 splice variants, IL-4δ2 and IL-4δ3, in humans, mice 
and cattle, which are formed from the removal of exon 2 or exon 3, respectively (6-9).  IL-4 
splice variant mRNA is translated into biologically inactive protein that acts as a competitive 
inhibitor for the IL-4 receptor, thus blocking IL-4 activation of other cells.  In a bovine model 
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of tuberculosis, a disease known to elicit a Th1 immune response, cattle that had increased 
levels of IL-4δ3 transcripts also had no visible lung pathology following Mycobacterium 
bovis infection (15).  This suggests a role for IL-4 splice variants in protection against Th1-
type infections.  In addition, Th2 responses are associated with greater full-length IL-4 to IL-
4 splice variant ratios (8, 16).  Based on this information, we hypothesized that full-length 
IL-4 mRNA would be dominantly expressed relative to IL-4 splice variant mRNA during 
RSV infection.  To test this, we used specific primer and probe sets for full-length IL-4, IL-
4δ2 and IL-4δ3 to determine which are induced in BRSV-infected AMΦs.  Our results show 
that the increases in IL-4 gene expression are in fact full-length transcripts, and not either of 
the splice variants.  Full-length IL-4 expression in BRSV-infected AMΦs was increased 7-
fold over mock-infected cells at 24hpi.   
 Recently, human AMΦs were shown to secrete IL-4 protein in response to phorbol-
12-myristate-13-acetate and calcium ionophore stimulation (10).  In our system, however, IL-
4 protein secretion was undetectable from either adult or neonatal AMΦs by ELISA.  The 
amount of IL-4 protein necessary to elicit an effective response is unknown.  It is possible 
that minimal but similar amounts of IL-4 protein elicit a stronger T cell response in neonates 
compared with adults, which could contribute to the disregulated Th2 response observed in 
asthmatic children with a previous history of RSV infection (1).  However, our data suggest 
that AMΦs are not a significant source of IL-4 protein during RSV infection in our model.  
IL-4 produced in the lung during RSV infection is likely to be secreted from another cell 
type, such as T cells or infiltrating monocytes (17-19).   
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 IL-10 is another anti-inflammatory cytokine produced by AMΦs that is a critical 
regulator of inflammation and homeostasis in the lung (20).  Previous work has shown 
increases in IL-10 gene expression in neonatal AMΦs infected with RSV, which could 
contribute to an overall anti-inflammatory environment in the lungs (5).  Here, we measured 
IL-10 protein by RSV-infected AMΦs.  Our data demonstrate increases in secreted IL-10 
protein in BRSV-infected and LPS-stimulated AMΦs from adults.  This data is supported by 
other studies documenting increases in IL-10 protein in AMΦs from adult humans (21).  
Interestingly, neonatal AMΦs did not secrete appreciable amounts of IL-10 protein in 
response to BRSV infection or mitogen stimulation.  Overall, our data suggest a restricted 
capacity of neonatal AMΦs to produce anti-inflammatory cytokines.   
This apparent deficiency in the ability of the neonatal AMΦs to produce key anti-
inflammatory cytokines could result in a disregulated and/or destructive pro-inflammatory 
response to RSV.  Our results demonstrate increases in IL-8 and IL-1β gene expression in 
RSV-infected AMΦs from both adults and neonates, with significantly more IL-1β 
transcripts produced in neonatal cells compared to adult cells.  No change in IL-6 gene 
expression was observed in RSV-infected AMΦs from either age group.    This observation 
differs from previous RSV studies which have reported increases in IL-6 from neonatal 
AMΦs or monocytes infected with RSV (5, 14, 22, 23).   
A major difference was observed between neonatal and adult AMΦ transcription of 
IL-1β.  Due to the significant increase in neonatal IL-1β mRNA transcription in response to 
RSV infection, we hypothesized that a coordinated increase in secreted IL-1β protein would 
be detected.  However, minimal IL-1β protein was detected from neonatal AMΦs infected 
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with BRSV or stimulated with PMA and ionomycin.  This disconnect between transcription 
of message and translation of protein could be explained by RSV interference with the post-
transcriptional or post-translational processing of IL-1β. 
Previous studies have reported equivocal results of IL-1β secretion in response to 
RSV infection.  Increased IL-1β mRNA and protein was shown in RSV-infected human cord 
blood monocytes, as well as in AMΦs from BALB/c mice at 6-8 weeks of age (24, 25).  
Significantly higher IL-1β protein levels, however, were detected in monocyte cell lysates 
compared to cell culture supernatants (25).  This suggests that intracellular IL-1β is not fully-
processed to form active and secreted IL-1β protein from RSV-infected cells.  IL-1β is 
normally synthesized as a precursor protein, pro-IL-1β, that is specifically cleaved by 
caspase-1 to expose a secretory signal sequence (26, 27).  Interferon regulatory factor-1 
(IRF-1) is a transcriptional activator of caspase-1, which is translated into pro-caspase-1, and 
requires cleavage by caspase-8 for activation (26).  Interference of any of these regulatory 
processes by RSV could effectively prevent the secretion of IL-1β protein from AMΦs, 
regardless of increased transcription or translation levels.  RSV has been shown to enhance 
IRF-1 and caspase-1 gene expression in a human alveolar epithelial cell line, however this 
response has not yet been investigated in AMΦs (24). 
Interestingly, we report that adult AMΦs secrete higher levels of IL-1β in response to 
mitogen stimulation than neonatal AMΦs, which could be a result of increased levels of 
caspase-1, caspase-8 or IRF-1 in stimulated adult AMΦs.  Interference with signaling 
pathways by RSV has previously been shown to modulate host cellular immune responses by 
blocking cytokine production (28, 29).  RSV NS2 protein inhibits IFNα/β signaling and host 
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anti-viral activity by mediating the degradation of Stat2, as a mechanism of evading the host 
immune response (28).  Both the NS1 and NS2 proteins of RSV have been shown to block 
the induction of type I interferons in epithelial cells and macrophages (28-30).  This 
mechanism of evasion utilized by RSV resulted in less pro-inflammatory cytokine 
expression, with decreased levels of RANTES, IL-8 and TNF-α (31).  Interaction of RSV 
and host signaling components may also play a role in the control of IL-1β regulation at the 
level of transcription, translation, or secretion. 
The second major aim of these studies was to elucidate the signaling pathways 
activated by RSV infection and provide insight into the mechanism of cytokine gene 
transcription and protein secretion in AMΦs.  To date, p38 MAPK signaling has been 
implicated in the expression of IL-10, IL-6, IL-β and IL-8 cytokine genes in macrophages 
(11, 32-35), although this is the first study to examine its role specifically in RSV-infected 
AMΦs from neonates and adults.  Here, we report that specifically blocking p38 MAPK 
activation with the chemical inhibitor SB203580 resulted in decreased levels of IL-8 and IL-
1β mRNA in response to RSV-infection or LPS-stimulation.  Our data suggest a role for p38 
MAPK signaling in cytokine production in RSV-infected AMΦs.  Interestingly, IL-10 
transcription was not affected by p38 MAPK inhibition, but IL-10 protein secretion from 
adult AMΦs was reduced, suggesting a role for p38 MAPK in the post-transcriptional 
processing of IL-10 mRNA in the RSV-infected AMΦ.  MAP kinase-activated protein kinase 
2 (MAPKAP-2) is one cellular target of active p38 which could become activated during 
RSV infection.  MAPKAP-2 activates AU-rich element-binding proteins which bind to AU-
rich regions in the 3’untranslated regions of mRNA transcripts to prevent self-folding and 
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degradation (36).  Preferential activation of MAPKAP-2 by RSV could function to stabilize 
IL-10 mRNA transcripts, which could explain the increases in IL-10 protein detected in cell 
culture supernatants without a preceding increase in transcription.   
In summary, our data indicate that AMΦ function is modulated by RSV infection.  
Based on this study, neonatal AMΦs are not a significant source of IL-4, IL-10 or IL-1β 
cytokines during RSV infection.  IL-10 protein secretion, as well as IL-6, IL-8 and IL-1β 
gene expression, was found to be dependent on p38 MAPK signaling.  Although increased 
IL-1β transcripts were detected in neonatal AMΦs, a corresponding increase in secreted 
protein was not observed.   Inadequate cytokine production by neonatal AMΦs may provide 
some explanation for the increase in host susceptibility to RSV and resultant secondary 
infections in infants.     
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Table 1.  Taqman primers and probe sets for detecting ovine IL-4. 
Primer name Sequence (5’-3’) Accession no. 
Full-length IL-4 Forward CAT GCA TGG AGC TGC CTG TA 
Full-length IL-4 Reverse AAT TCC AAC CCT GCA GAA GGT 
Full-length IL-4 Probe FAM-TGC TGC CCC AAA GAA CGC AAC TG-TAMRA 
NM_001009313 
Il-4δ2 Forward AGA GAT CAT AA AAC GCC GAA CAT 
IL-4δ2 Reverse CTC AAT TCC AGT CCT ACA GAA 
IL-4δ2 Probe FAM-CCT CAC ATC GCA GAA GAA CGC AAC TGA GAA GGA-TAMRA 
NM_001009313 
IL-4δ3 Forward CAT GCA TGG AGC TGC CTG TA 
IL-4δ3 Reverse CGT ACT TGT ACT CGT CTT GGC 
IL-4δ3 Probe FAM-TGC CCC AAA GAC CTG TTC TGT GAA TGA A-TAMRA 
NM_001009313 
Polyubiquitin 3’UTR Forward GGT GGC TGT TAA TTC TTC AG 
Polyubiquitin 3’UTR Reverse AA TGG CTA GAG TGC AGA ACG AT 
Polyubiquitin 3’UTR Probe FAM-TTC ATA ATG CTC AGT GAT GG-MGBNFQ 
NM_001009202 
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Table 2.  SYBR green primer sets for detecting ovine cytokine genes. 
Primer name Sequence (5’-3’) Accession number 
IL-4 Forward GGA CTT GAC AGG AAT CTC 
IL-4 Reverse CTC AGC GTA CTT GTA CTC 
Z11897 
IL-10 Forward GAT GCC ACA GGC TGA GAA CC 
IL-10 Reverse GCG AGT TCA CGT GCT CCT TG 
U11421 
IL-6 Forward GAG TTG CAG AGC AGT ATC 
IL-6 Reverse GGC TGG AGT GGT TAT TAG 
X62501 
IL-8 Forward AAG CTG GCT GTT GCT CTC 
IL-8 Reverse GGC ATCAGAA GTT CTG TAC TC 
X78306 
IL-1β Forward ATG GGT GTT CTG CAT GAG 
IL-1β Reverse AAG GCC ACA GGA ATC TTG 
X54796 
Polyubiquitin 3’UTR Forward GGT GGC TGT TAA TTC TTC AG 
Polyubiquitin 3’UTR Reverse AA TGG CTA GAG TGC AGA ACG AT 
NM_001009202 
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Figure 1:  Relative quantification of full-length IL-4 mRNA transcripts expressed in 
response to stimulation with PMA and ionomycin or BRSV, compared with mock-treated 
cells.  AMΦs isolated from adult (n=6) or neonatal (n=8) sheep lungs were stimulated in 
vitro with PMA (1μg/ml) and ionomycin (0.5μg/ml) or BRSV (moi = 1).  Cells were lysed at 
various timepoints for total RNA isolation.  Total RNA was used as template for RT-PCR 
reactions using SuperScriptIII Platinum One-Step qRT-PCR kit (Invitrogen).  BRSV and 
PMA/ionomycin treatments both induced full-length IL-4 mRNA transcription.  Data are 
representative of 3 separate experiments. 
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Figure 2:  Relative quantification of IL-10 mRNA expression in ovine AMΦs in response to 
in vitro stimulation.  AMΦs isolated from adult sheep (n=8) and neonatal lambs (n=8) were 
preincubated with p38 MAPK inhibitor SB203580 for 1h.  BRSV (moi =1) was added for 90 
min and then cells were washed.  LPS (1μg/ml) was added to a subset of adult AMΦs.  Cells 
were lysed at designated timepoints and total RNA isolated.  Oligo(dT) cDNA was 
transcribed and used as template for SYBR green real-time PCR.  Results are reported as 
fold-changes in expression compared to mock-treated cells normalized to endogenous 
control, ovine polyubiquitin.  No significant differences were observed in neonatal AMΦs or 
adult AMΦs pre-treated with SB203580, treated with BRSV or LPS.  Data are representative 
of 4 separate experiments. 
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Figure 3:  IL-10 protein secretion (units/mL) by ovine AMΦs following p38 MAPK 
inhibition and in vitro BRSV or mitogen stimulation.  AMΦs isolated from neonates (n=8) 
and adults (n=8) were pre-incubated with p38 MAPK inhibitor, SB203580, for 1h.  BRSV 
(moi=1), PMA (1μg/ml) and ionomycin (0.5μg/ml), and LPS (1μg/ml) were added to 
designated wells.  Cell culture supernatants were harvested at 48h and frozen at -80C until 
use.  Secreted IL-10 was measured by ELISA in IL-10 ELISA units/mL as determined by 
recombinant bovine IL-10 standard curve.  In general, neonatal AMΦs (A) did not secrete 
appreciable amounts of IL-10 protein following BRSV infection or stimulation with 
PMA/ionomycin.  In adult AMΦs (B), treatment with either BRSV, LPS or PMA/ionomycin 
induced an increase in IL-10 protein secretion compared to mock-treated cells.  Pre-treatment 
with SB203580 decreased average levels of IL-10 protein in cell-culture supernatants in  
mock-, BRSV- and LPS-treated AMΦs.  Data are representative of 4 separate experiments. 
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 Figure 3. IL-10 protein secretion (units/mL) by ovine AMΦs following p38 MAPK inhibition and in vitro BRSV or mitogen 
stimulation.   
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Figure 4:  Relative quantification of pro-inflammatory cytokine gene transcripts produced by 
AMΦs stimulated in vitro.  Neonatal (n=8) and adult (n=8) AMΦs were pre-incubated with 
p38 MAPK inhibitor, SB203580, for 1h prior to treatment with BRSV (moi=1) or LPS 
(1μg/ml).  Cells were lysed in RLT buffer and total RNA isolated for cDNA synthesis.  
Oligo(dT) cDNA template was used for real-time PCR assay with SYBR green chemistry.  
Results are reported as fold-change in expression compared to mock-treated cells normalized 
to ovine polyubiquitin as an endogenous control.   No significant differences were observed 
in IL-6 mRNA transcripts between mock- and BRSV-treated AMΦs in neonates or adults, 
while LPS-treatment of adult AMΦs induced a two-fold increase in expression (A).  IL-8 and 
IL-1β gene expression was significantly increased in neonatal AMΦs treated with BRSV 
compared with control cells (p<0.01), while significant increases in adult AMΦ IL-8 and IL-
1β gene transcripts were observed only in LPS-treated cells (p<0.05) (B) and (C).  Data are 
representative of 4 separate experiments.  
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Figure 4.  Relative quantification of pro-inflammatory cytokine gene transcripts produced by 
AMΦs stimulated in vitro.   
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Figure 5:  IL-1β protein secretion by ovine AMΦs following p38 MAPK inhibition and in 
vitro BRSV or mitogen stimulation.  AMΦs isolated from neonates (n=8) and adults (n=8) 
were pre-incubated with p38 MAPK inhibitor, SB203580, for 1h.  BRSV (moi=1), PMA 
(1μg/ml) and ionomycin (0.5μg/ml), and LPS (1μg/ml) were added to designated wells.  Cell 
culture supernatants were harvested at 24h and frozen at -80C until use.  In general, neonatal 
or adult AMΦs did not secrete appreciable amounts of IL-1β protein following BRSV 
infection.  Data are representative of 4 separate experiments.
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Figure 5.  IL-1β protein secretion by ovine AMΦs following p38 MAPK inhibition and in vitro BRSV or mitogen stimulation (24h) 
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Figure 6:  IL-1β protein secretion by ovine AMΦs following p38 MAPK inhibition and 
in vitro BRSV or mitogen stimulation.  AMΦs isolated from neonates (n=8) and adults 
(n=8) were pre-incubated with p38 MAPK inhibitor, SB203580, for 1h.  BRSV (moi=1), 
PMA (1μg/ml) and ionomycin (0.5μg/ml), and LPS (1μg/ml) were added to designated 
wells.  Cell culture supernatants were harvested at 48h and frozen at -80C until use.  In 
general, neonatal or adult AMΦs did not secrete appreciable amounts of IL-1β protein 
following BRSV infection.  Data are representative of 4 separate experiments. 
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Figure 6.  IL-1β protein secretion by ovine AMΦs following p38 MAPK inhibition and in vitro BRSV or mitogen stimulation (48h)
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CHAPTER 3.  GENERAL CONCLUSIONS 
GENERAL DISCUSSION 
 RSV remains the leading cause of lower respiratory tract illness in infants worldwide.  
Nearly 70% of children are infected by the age of 1, and nearly 100% are infected by the age 
of 2, with high rates of reinfection (1, 2).  This is likely a result of an ineffective immune 
response to RSV mounted in the neonate, leaving them susceptible to serious secondary 
infections in addition to RSV infection alone.  Alveolar macrophages (AMΦs) are critical 
innate immune cells in the lung, as first-defenders against inhaled antigens (3).  In addition to 
pathogen recognition and antigen presentation, cytokine production by AMΦs helps to shape 
adaptive immune responses in the lung.  The studies described here explored the role of 
AMΦ during RSV infection in neonates compared to adults in terms of cytokine expression 
and secretion.  Based on previous work, RSV infection induces a mixed cytokine response in 
AMΦs as determined by the upregulation of both pro- and anti-inflammatory cytokine genes 
in neonates (4).  However, based on these current experiments, there appear to be functional 
differences in the ability of the neonatal AMΦ to secrete cytokine protein compared with 
adult AMΦs.     
Objective 1.  The production of IL-4 splice variant mRNA could potentially protect against 
IL-4 responses induced by RSV infection.  As described previously, IL-4δ2 and IL-4δ3 are 
normally coexpressed with full length IL-4 and result from removal of either exon 2 or exon 
3 from full length IL-4 mRNA (5, 6).  IL-4 splice variants have been shown to be 
preferentially expressed in cattle that were protected following natural exposure to 
Mycobacterium bovis in a bovine tuberculosis model (7).  This suggests a role for IL-4 splice 
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variants in the Th1-type immune response elicited by M. bovis (6, 7).  In another study, 
human patients with chronic asthma had increased full-length IL-4 to IL-4δ2 ratios compared 
to healthy control subjects (8).  Based on this information, we hypothesized that the ratio of 
full-length IL-4 to IL-4 splice variants expressed in AMΦs following BRSV infection would 
be similarly increased compared to mock-infected controls. 
 This set of experiments compared full-length IL-4 and IL-4 splice variant expression 
in response to BRSV infection.  In vitro BRSV infection of sheep AMΦs induced the 
transcription of full-length IL-4.  No IL-4 splice variant mRNA, however, was detected in 
any of the test samples.  This could be due to the fact that IL-4δ2 and IL-4δ3 are expressed 
infrequently or intermittently in sheep AMΦs, regardless of infection state. 
Objective 2.  These experiments determined if the increases seen in IL-4 mRNA in RSV-
infected AMΦs results in an increased level of secreted IL-4 protein, which could contribute 
to the overall Th2 environment seen during RSV infection in both neonates and adults (9-12).  
Increased IL-4 secretion from neonatal AMΦs could help in explaining more severe disease 
seen in infants compared with adults.  Here, we measured IL-4 protein by sandwich ELISA.  
In our system, secreted IL-4 protein was not detected from adult or neonatal AMΦs 
following BRSV infection or mitogen stimulation.  This suggests that AMΦs are not a 
significant source of IL-4 protein, and IL-4 production during RSV infection is likely from 
another cell type in the lung such as activated T cells or infiltrating monocytes.   
Objective 3.  After determining that AMΦs are not a likely source of IL-4 protein during 
RSV infection, we examined whether they produce another critical anti-inflammatory 
mediator, IL-10.  IL-10 has been shown to inhibit Th1 cytokine production as well as 
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antigen-presenting cell functions (13, 14).  In the lung, IL-10 is produced by alveolar 
macrophages in response to LPS stimulation and viral infections, including RSV (15-17).  
Increases in IL-10 secretion by BRSV-infected AMΦs could suppress Th1 responses and 
contribute to the overall Th2 cytokine bias in the lung.  In this study, neonatal AMΦs did not 
secrete appreciable amounts of IL-10 in response to BRSV infection or mitogen stimulation.  
Adult AMΦs, however, produced IL-10 protein following BRSV infection, and stimulation 
with LPS or the combination of PMA and ionomycin.  This suggests that IL-10 production 
may contribute to the decreased susceptibility of adults to RSV infection.     
Objective 4.  Because RSV pathogenesis is associated with a mixed immune response and 
the production of both immunomodulatory and proinflammatory mediators, AMΦ production 
of proinflammatory cytokines may contribute to the differences observed in the severity of 
disease observed in neonates compared to adults.  Here, we assessed proinflammatory IL6, 
IL-8 and IL-1β cytokine expression in RSV-infected AMΦs from neonates and adults by 
real-time PCR with SYBR green.  While no change was observed in IL-6 transcription in 
neonatal or adult AMΦs in response to BRSV infection, IL-8 and IL-1β expression were both 
increased.  An interesting difference between neonatal and adult AMΦs was noted in the 
transcription of IL-1β following BRSV infection, with significantly higher expression from 
neonatal cells.  Based on this observation, we hypothesized that the increases in IL-1β gene 
transcription will lead to increases in IL-1β protein secretion by AMΦs in response to RSV 
infection, with higher levels from neonatal AMΦs.  Surprisingly, RSV infection did not 
induce IL-1β protein secretion in our system.  This observation suggests a post-
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transcriptional control mechanism employed by the virus which would limit the pro-
inflammatory response.   
 The secretion of active IL-1β is a highly regulated event.  IL-1β is first synthesized as 
an inactive precursor, pro-IL-1β, which must be specifically cleaved by caspase-1 for 
activation (18, 19).  Caspase-1 itself is synthesized as inactive pro-caspase-1 in response to 
interferon regulatory factor-1 (IRF-1), and requires cleavage by caspase-8 for its own 
activation (18).  Blocking any of these critical regulatory steps would prevent the effective 
secretion of IL-1β from BRSV-infected AMΦs, which could contribute to the disease 
susceptibility of neonates.         
Objective 5.  These experiments explored the role of p38 MAPK signaling in BRSV-infected 
AMΦs from neonates and adults.  p38 has been shown to be required for cytokine gene 
expression in other models and cell types (17, 20-23), and here we describe its role in BRSV-
infected AMΦs.  Neonatal and adult AMΦs were pre-incubated with a specific chemical 
inhibitor of p38 MAPK, SB203580, for 1h prior to in vitro BRSV infection.   Inhibition of 
p38 MAPK effectively reduced IL-8 and IL-1β gene transcription in response to BRSV-
infection or LPS-stimulation.  IL-10 protein secretion from adult AMΦs was also reduced in 
those cells pre-incubated with SB203580 prior to stimulation with BRSV or LPS.  This 
observation, along with the fact that IL-10 message was not significantly different in 
SB203580-treated AMΦs compared to those pre-incubated with culture medium alone, 
suggests a role for p38 MAPK in addition to its known role of initiation of transcription.  A 
cytoplasmic target of p38 MAPK, MAPK-activated protein kinase-2 (MAPKAP-2), 
functions to stabilize mRNA transcripts by activating AU-rich element-binding proteins.  
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These proteins bind to AU-rich regions in the 3’untranslated regions of mRNAs and enhance 
stability by preventing self-folding and degradation of the transcripts (24).  By inhibiting p38 
MAPK activation of MAPKAP-2, the decreased stability of mRNA transcripts could lead to 
the reduced amount of secreted protein.  Based on our findings, manipulation of this pathway 
by RSV could lead to increased cytokine gene transcripts and protein in infected AMΦs. 
RECOMMENDATIONS FOR FUTURE RESEARCH 
 The findings reported in this thesis only scratch the surface of intracellular signaling 
pathways utilized during RSV infection of AMΦs.  We report an essential role for p38 
MAPK signaling on both cytokine gene transcription as well as IL-10 protein secretion.  p38 
MAPK is one of three major MAPK enzymes, along with ERK and JNK.  Different specific 
chemical inhibitors are available for blocking ERK and JNK activation, and could be used to 
explore their role in cytokine production by RSV-infected AMΦs.  One study, using human 
AMΦs stimulated with LPS, implicated a role for ERK and JNK for IL-10 production (17) 
although this has yet to be described during RSV infection.  It would also be interesting to 
focus on the upstream activators and downstream targets of each of the MAPK proteins.  The 
effect of RSV on total protein levels and phosphorylation states of MAPK proteins and their 
regulators in AMΦs could help describe the mechanism responsible for cytokine expression 
and production in these cells.  Further description of the mechanisms leading to differential 
regulation of cytokine production in neonatal and adult AMΦs during RSV infection could 
help explain the differences in disease susceptibility and severity seen in neonates. 
 Another interesting direction to take would be to further explore the regulation of IL-
1β in the neonatal AMΦ.  As described, IL-1β protein is formed as an inactive precursor, 
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pro-IL-1β, that is cleaved by caspase-1 prior to secretion.  Caspase-1 itself is 
transcriptionally regulated by IRF-1, and requires cleavage by caspase-8 to become fully 
active (18).  In a human epithelial cell line, RSV induced increased caspase-1 transcription 
and secretion following increased IRF-1 induction, although this has not been described for 
AMΦs (19).  Examining the levels of IRF-1, caspase-1, and caspase-8 could provide 
important insight into the observed disconnect between IL-1β gene transcription and protein 
secretion from neonatal AMΦs infected with BRSV.     
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